The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

Inclusion Criteria: * Adult subjects who are 20 to 65 years old (inclusive), of either gender and in any ethnical group in Asia. * Chronic hepatitis C, positive with both antibody to hepatitis C virus (anti HCV) and HCV RNA assays. * Confirmed HCV genotype 1. * Subjects who are indicated to have combination treatment of PegIFNα 2a and RBV at the discretion of the investigator. * All fertile males and females receiving RBV must be using two forms of effective contraception during treatment with study drugs and 6 months post treatment completion. * Subjects must voluntarily give written informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. * Subjects must be able to comply with the assessments during the study. * Subjects must be able to understand study QoL questionnaires. Exclusion Criteria: * Prior treatment with any IFN α or any medicines that contain Cordyceps. * Prior treatment of hepatitis C with any other antiviral or immune modulators. * Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study. * Subjects diagnosed with hepatocellular carcinoma (HCC) by biopsy or α fetoprotein (AFP) serology and radiology (helical computed tomography \[CT\] and/or magnetic resonance imaging \[MRI\]) within 5 years of signing the informed consent form. * Evidence of hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy). * History or evidence of other liver diseases other than chronic HCV infection. * Subjects with known allergy or hypersensitivity to any ingredient of the study drug or placebo. * Pregnant, planning on becoming pregnant, or breastfeeding female subject or male subject whose partner is pregnant or planning on becoming pregnant. * Subject with any of the following laboratory abnormalities: 1. Platelet count \<90,000/mm3; 2. Absolute neutrophil count \<1500 cells/mm3; 3. Hemoglobin \<12 g/dL for women and \<13 g/dL for men; 4. Creatinine \>1.5 mg/dL; 5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>10 x upper limit of normal (ULN); 6. Total serum bilirubin \>1.5 x ULN; 7. Subjects without cirrhosis and AFP \>50 ng/mL must have an ultrasound between the screening and baseline visit with no findings suspicious for HCC. * Medical conditions which are contraindications for PegIFNα 2a or RBV therapy: 1. Psychiatric disorders; 2. Organ transplant (other than cornea or hair transplant or skin graft); 3. Severe concurrent medical disease such as severe hypertension, significant coronary heart disease, poorly controlled diabetes mellitus (glycated hemoglobin A1c \[HbA1c\] \>8.5%), not adequately controlled thyroid dysfunction, chronic obstructive pulmonary disease, severe infections (bacterial, viral, fungal, including acute tuberculosis), or hemoglobinopathies (thalassemia major or sickle cell anemia); 4. Autoimmune hepatitis or other autoimmune conditions known to be exacerbated by PegIFNα 2a and RBV. * History of a severe seizure disorder or current anticonvulsant use. * Evidence of severe retinopathy (e.g., cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (e.g., due to diabetes mellitus or hypertension). * Other cases judged by the investigator to be ineligible for participation in the study.